Skip to content

HCC Screening Using DNA Methylation Changes in ctDNA

Clinical Trials on detection of hepatocellular carcinoma (HCC) with non-invasive method based on DNA methylation of circulated tumor DNA, PBMC and T cells

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800018467
Enrollment
Unknown
Registered
2018-09-20
Start date
2018-09-30
Completion date
Unknown
Last updated
2018-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cancer

Interventions

Gold Standard:The diagnose will be confirmed using AASLD practice guideline for chronic Hepatitis B
of&#32
to&#32
cancer

Sponsors

Beijing Epidial Medical Diagnosis Technology Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: For HCC patient inclusion criteria include confirmed diagnosis of HCC by EASL-EORTC guidelines and confirmed hepatitis B diagnosis for HepB patients using AASLD practice guidelines. Healthy controls will be matched to the patient group for age, sex, smoking and alcohol consumption. Whole-blood specimens will be ideally collected before start of standard therapy.

Exclusion criteria

Exclusion criteria: For HCC a strict exclusion criterion is cirrhosis, any other known inflammatory disease (bacterial or viral infection with the exception of hepatitis B or C, diabetes, asthma, autoimmune disease, active thyroid disease) which could alter T cells and monocytes characteristics as well as other cancers. For HepB patient exclusion criteria in addition to the above will be diagnosis of HCC or any other cancer. For healthy controls, exclusion criteria include any known inflammatory or infectious disease including HepB and HepC and any diagnosis of chronic disease, cancer, medications use, or drugs of abuse.

Design outcomes

Primary

MeasureTime frame
Methylation level of the target genes;

Countries

China

Contacts

Public ContactNing Li

Beijing Youan Hospital, Capital Medical School, Beijing, China

liningbjyah@vip.sina.com+86 10 8399 7599

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026